About Arrowhead Research CorporationArrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate ™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and ARC-F12 for hereditary angioedema and thromboembolic diseases. For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research Corporation. Source: Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on September 24, 2015, with a presentation starting at 11:00 a.m. EDT to discuss ARC-520, its candidate for the treatment of chronic hepatitis B infection. During the event, Arrowhead management and a panel of key opinion leaders will discuss results of the Heparc-2001 Phase 2a study and results of a nonclinical study conducted in 9 chimpanzees chronically infected with hepatitis B virus. Guest speakers at the event include: Robert G. Gish, M.D.Medical Director, Hepatitis B FoundationClinical Professor of Medicine, University of Nevada, Las VegasSenior Medical Director, St. Joseph's Hospital and Medical CenterClinical Professor of Medicine (Consultant), Stanford Hospital and Medical Center Stephen A. Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)Head of Research and Molecular Development, Victorian Infectious Diseases Reference LaboratoryDirector of WHO Collaborating Centre for Virus Reference and Research Robert E. Lanford, PhDDirector of Southwest National Primate Research Center (SNPRC)Scientist, Virology and Immunology and SNPRC, Texas BioMedical Research Institute A live and archived version of the webcast, including presentation slides, will be available on the events section of the Company's website at ir.arrowheadresearch.com/events.cfm. To access an audio only version of the live presentation, dial 855-215-6159 toll-free from the U.S. or 315-625-6887 for international callers and enter Conference ID 19541930. About ARC-520 Arrowhead's RNAi-based candidate ARC-520 is being investigated in the treatment of chronic HBV infection. The small interfering RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of the reverse transcription process where current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC-520 specifically, to determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. Arrowhead has completed a Phase 1 single ascending dose study in normal volunteers and the company is conducting single dose Phase 2a studies and multiple dose Phase 2b studies in chronic HBV patients. Approximately 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally.